| 产品详情 |
| Edit |   |
|---|
| Product Name | P2Y Antagonist II |
|---|
| Description | Purity ~99% (HPLC). A phenoxypyridinyl-phenylurea that acts as a highly selective P2Y1 antagonist (Ki = 6nM against 0.5nM 2-MeS-ADP for human P2Y1 binding), while displaying much reduced or no affinity toward other P2Y family GPCRs (Ki = ≥2.5uM toward hP2Y14; Ki >15uM toward human P2Y2, P2Y6, P2Y11, and P2Y12). Effectively inhibits 2.5uM ADP-induced platelet aggregation in vitro (IC50 = 2.1uM) and reduces FeCl2-induced carotid artery blood clot formation in anesthetized rats in vivo (10mg/kg/h i.v. infusion) with much less effect toward prolonging cuticle and mesenteric bleeding time when compared to another P2Y12 antagonist Clopidogrel. Pharmackinetic studies reveal only moderate oral bioavailability in rat. Solubility: DMSO Primary Target: P2Y1 |
|---|
| Size | 10mg |
|---|
| Concentration | n/a |
|---|
| Applications | n/a |
|---|
| Other Names | P2Y Antagonist II (1-(2-(2-tert-Butylphenoxy)pyridin-3-yl)-3-(4-(trifluoromethoxy)phenyl)urea, Purinergic Receptor P2Y Antagonist II) |
|---|
| Gene, Accession, CAS # | n/a |
|---|
| Catalog # | 217615 |
|---|
| Price | |
|---|
| Order / More Info | P2Y Antagonist II from UNITED STATES BIOLOGICAL |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|